Paying users zone. Data is hidden behind: .
Get 1-month access to Regeneron Pharmaceuticals Inc. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Adjustments to Financial Statements
Advanced level
Adjustments to Total Assets
Regeneron Pharmaceuticals Inc., adjusted total assets
US$ in thousands
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »
2 Deferred tax assets. See details »
Adjustments to Current Liabilities
Regeneron Pharmaceuticals Inc., adjusted current liabilities
US$ in thousands
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| As Reported | ||||||
| Current liabilities | ||||||
| Adjustments | ||||||
| Less: Deferred revenue, current portion | ||||||
| After Adjustment | ||||||
| Adjusted current liabilities | ||||||
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
Adjustments to Total Liabilities
Regeneron Pharmaceuticals Inc., adjusted total liabilities
US$ in thousands
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 Operating lease liability (before adoption of FASB Topic 842). See details »
2 Deferred tax liabilities. See details »
Adjustments to Stockholders’ Equity
Regeneron Pharmaceuticals Inc., adjusted stockholders’ equity
US$ in thousands
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 Net deferred tax assets (liabilities). See details »
Adjustments to Capitalization Table
Regeneron Pharmaceuticals Inc., adjusted capitalization table
US$ in thousands
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 Operating lease liability (before adoption of FASB Topic 842). See details »
2 Operating lease liabilities (included in Accrued expenses and other current liabilities). See details »
3 Operating lease liabilities (included in Other noncurrent liabilities). See details »
4 Net deferred tax assets (liabilities). See details »
Adjustments to Revenues
Regeneron Pharmaceuticals Inc., adjusted revenues
US$ in thousands
| 12 months ended: | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|---|---|
| As Reported | ||||||
| Revenues | ||||||
| Adjustment | ||||||
| Add: Increase (decrease) in deferred revenue | ||||||
| After Adjustment | ||||||
| Adjusted revenues | ||||||
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
Adjustments to Reported Income
Regeneron Pharmaceuticals Inc., adjusted net income
US$ in thousands
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 Deferred income tax expense (benefit). See details »